VIDEO: Emerging therapies for mantle cell lymphoma

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

There's a couple emerging therapies that folks should keep their eye on. The first one I'll mention is Pirtobrutinib. This is like a third generation BTK inhibitor. It's considered a non-covalent BTK inhibitor, and Pirtobrutinib actually got FDA approval for mantle cell lymphoma back in January for patients who have failed a covalent BTK inhibitor. So it's now commercially available. The response rates for Pirtobrutinib in patients who have failed a prior BTK inhibitor are running somewhere in the 50% range, so that's pretty impressive. And right now there's a very important, ongoing, randomized phase three trial comparing Pirtobrutinib head-to-head against first and second generation BTK inhibitors. And so this study is enrolling as we speak. It's probably will finish enrollment in the next six to 12 months. Probably be a little while before we have the readout from that study. But you know, if Pirtobrutinib is the winner in that trial, it could leap frog other BTK inhibitors as the BTK inhibitor of choice. It has a amazingly good safety and toxicity profile so patients who are on Pirtobrutinib are generally very happy. The other drug I'll mention that we only have some early data on but I think looks promising is a bispecific monoclonal antibody called Glofitamab. We saw some data from this at the ASH meeting. Not a lot of patients treated to date, but the majority of patients who received this investigational bispecific monoclonal antibody with relapsed mantle cell lymphoma responded to treatment. We don't know a ton about the durability of these responses yet, but we do see the majority of patients responding and relapsed mantle cell lymphoma can be very difficult to deal with so to get a new agent with a high response rate, that's pretty promising. So we're very excited to see further development of Glofitamab in relapsed mantle cell lymphoma.